Sansure Biotech, Inc. (688289) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Sansure Biotech, Inc.

Why is Sansure Biotech, Inc. ?

Poor long term growth as Net Sales has grown by an annual rate of -21.62% and Operating profit at -51.32% over the last 5 years

The company has declared Negative results for the last 10 consecutive quarters

OPERATING CASH FLOW(Y) Lowest at CNY 187.18 MM
DEBT-EQUITY RATIO (HY) Highest at -40.6 %
INTEREST(Q) Highest at CNY 6.13 MM

With ROE of 2.60%, it has a very attractive valuation with a 1.64 Price to Book Value

Over the past year, while the stock has generated a return of -15.24%, its profits have fallen by -49.9%
At the current price, the company has a high dividend yield of 2.7

Below par performance in long term as well as near term

Along with generating -15.24% returns in the last 1 year, the stock has also underperformed China Shanghai Composite in the last 3 years, 1 year and 3 months

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to Sansure Biotech, Inc. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Sansure Biotech, Inc. for you?

Medium Risk, Low Return

Absolute

Risk Adjusted

Volatility

Sansure Biotech, Inc.

-19.64%

-0.04

31.79%

China Shanghai Composite

13.33%

1.58

14.20%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-21.62%

EBIT Growth (5y)

-51.32%

EBIT to Interest (avg)

100.00

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.50

Sales to Capital Employed (avg)

0.24

Tax Ratio

11.45%

Dividend Payout Ratio

108.99%

Pledged Shares

Institutional Holding

ROCE (avg)

87.81%

ROE (avg)

18.63%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

1.64

EV to EBIT

60.23

EV to EBITDA

25.62

EV to Capital Employed

2.10

EV to Sales

5.52

PEG Ratio

Dividend Yield

2.66%

ROCE (Latest)

3.49%

ROE (Latest)

2.60%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Dow Theory

Mildly Bearish

OBV

No Trend

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

5What is working for the Company

NET SALES(HY)

At CNY 768.65 MM has Grown at 19.8%

RAW MATERIAL COST(Y)

Fallen by -8.63% (YoY

-20What is not working for the Company

OPERATING CASH FLOW(Y)

Lowest at CNY 187.18 MM

DEBT-EQUITY RATIO (HY)

Highest at -40.6 %

INTEREST(Q)

Highest at CNY 6.13 MM

OPERATING PROFIT(Q)

Lowest at CNY -0.88 MM

OPERATING PROFIT MARGIN(Q)

Lowest at -0.23 %

PRE-TAX PROFIT(Q)

Lowest at CNY 23.04 MM

NET PROFIT(Q)

Lowest at CNY 28.11 MM

EPS(Q)

Lowest at CNY 0.04

Here's what is working for Sansure Biotech, Inc.

Net Sales

At CNY 768.65 MM has Grown at 19.8%

Year on Year (YoY)

MOJO Watch

Near term sales trend is positive

Net Sales (CNY MM)

Raw Material Cost

Fallen by -8.63% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Sansure Biotech, Inc.

Operating Cash Flow

Lowest at CNY 187.18 MM and Fallen

In each year in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (CNY MM)

Interest

At CNY 6.13 MM has Grown at 14.81%

period on period (QoQ)

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (CNY MM)

Debt-Equity Ratio

Highest at -40.6 % and Grown

In each half year in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Interest

Highest at CNY 6.13 MM

in the last five periods and Increased by 14.81% (QoQ)

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (CNY MM)

Operating Profit

Lowest at CNY -0.88 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is negative

Operating Profit (CNY MM)

Operating Profit Margin

Lowest at -0.23 %

in the last five periods

MOJO Watch

Company's profit margin has deteriorated

Operating Profit to Sales

Pre-Tax Profit

Lowest at CNY 23.04 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (CNY MM)

Pre-Tax Profit

Fallen at -37.62%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (CNY MM)

Net Profit

Lowest at CNY 28.11 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is negative

Net Profit (CNY MM)

EPS

Lowest at CNY 0.04

in the last five periods

MOJO Watch

Declining profitability; company has created lower earnings for shareholders

EPS (CNY)

Non Operating Income

Highest at CNY 1.28 MM

in the last five periods

MOJO Watch

Increased income from non business activities may not be sustainable

Non Operating income